Profile
Edward F.
Kessig is the founder of FX2 Virtual Impact.
Former jobs include Director-North American Sales at INO Therapeutics LLC, Senior Vice President-Commercial at Antares Pharma, Inc. from 2018 to 2020, Senior Vice President-Sales at Auxilium Pharmaceuticals LLC from 2004 to 2012, Vice President-Commercial Operations at Nuro Pharma, Inc., and Vice President-Sales at Lipocine, Inc. Education includes an MBA from St. John's University.
Edward Kessig active positions
| Companies | Position | Start |
|---|
Former positions of Edward Kessig
| Companies | Position | End |
|---|---|---|
| ANTARES PHARMA, INC. | Corporate Officer/Principal | 20/07/2020 |
| AUXILIUM PHARMACEUTICALS, INC. | Sales & Marketing | 06/02/2012 |
INO Therapeutics LLC
INO Therapeutics LLC Pharmaceuticals: MajorHealth Technology Develops pharmaceutical drugs | Sales & Marketing | - |
Nuro Pharma, Inc. | Corporate Officer/Principal | - |
| LIPOCINE INC. | Sales & Marketing | - |
Training of Edward Kessig
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Antares Pharma, Inc.
Antares Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops parenteral pharmaceutical products | Health Technology |
Auxilium Pharmaceuticals LLC
Auxilium Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceutical products | Health Technology |
Nuro Pharma, Inc. | |
St. John's University
St. John's University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
INO Therapeutics LLC
INO Therapeutics LLC Pharmaceuticals: MajorHealth Technology Develops pharmaceutical drugs | Health Technology |
Lipocine, Inc.
Lipocine, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that engages in research and development for the delivery of drugs | Health Technology |
- Stock Market
- Insiders
- Edward Kessig
















